Test Overview
Test Methodology

EIA

Test Usage

Anti-NXP-2 antibodies are present in 1.6-30% of adult DM and 18-25% of JDM. In JDM they are associated with cutaneous calcinosis cutis. In adult DM they are significantly associated with the presence of cancer (cancer was found in 13.6% of Anti-NXP-2 positive DM patients). Anti-MDA5 antibodies are present in 7-35% of adult DM. Features consist of absent or mild muscle symptoms (CADM); associated with rapidly progressive ILD; specific mucocutaneous features of skin ulcerations and papules; higher risk of oral ulcerations and arthritis.

Test Details
Analytic Time

7 days

Soft Order Code
RNXP2
MiChart Code
Anti-NXP2
Synonyms
  • Anti-NXP2
  • NXP-2 (P140)
Laboratory
Sendout
Reference Laboratory
RDL Reference Laboratories 174
Section
Special Testing
Specimen Requirements
Collection

Collect specimen in an SST tube. Centrifuge, aliquot serum into a plastic vial and refrigerate.

Yellow Top Tube
Normal Volume
1 mL serum
Minimum Volume
0.5 mL serum
Additional Information

Test sent to RDL Reference Laboratories.

Billing
CPT Code
83516
Fee Code
AA933
NY State Approved
No